tetano
Editor, Senior Moderator
Biotechnol Genet Eng Rev
. 2022 Sep 19;1-22.
doi: 10.1080/02648725.2022.2122297. Online ahead of print.
Bacterial co-infections and antimicrobial resistance associated with the Coronavirus Disease 2019 infection
Addisu D Teklemariam[SUP] 1 [/SUP], Anwar M Hashem[SUP] 2 3 [/SUP], Saber H Saber[SUP] 4 [/SUP], Mohammed S Almuhayawi[SUP] 2 [/SUP], Shafiul Haque[SUP] 5 [/SUP], Turki S Abujamel[SUP] 3 6 [/SUP], Steve Harakeh[SUP] 7 8 [/SUP]
Affiliations
Abstract
Bacterial co-infections are typically associated with viral respiratory tract infections and pose a significant public health problem around the world. COVID-19 infection damages tissues lining the respiratory track and regulates immune cells/cytokines leading to microbiome dysbiosis and facilitating the area to be colonized by pathogenic bacterial agents. There have been reports of different types of bacterial co-infection in COVID-19 patients. Some of these reports showed despite geographical differences and differences in hospital settings, bacterial co-infections are a major cause of morbidity and mortality in COVID-19 patients. The inappropriate use of antibiotics for bacterial infections, particularly broad-spectrum antibiotics, can also further complicate the infection process, often leading to multi drug resistance, clinical deterioration, poor prognosis, and eventually death. To this end, researchers must establish a new therapeutic approach to control SARS-CoV-2 and the associated microbial coinfections. Hence, the aim of this review is to highlight the bacterial co-infection that has been recorded in COVID-19 patients and the status of antimicrobial resistance associated with the dual infections.
Keywords: Bacteria; COVID-19; SARS-CoV-2; co-infection; patients.
. 2022 Sep 19;1-22.
doi: 10.1080/02648725.2022.2122297. Online ahead of print.
Bacterial co-infections and antimicrobial resistance associated with the Coronavirus Disease 2019 infection
Addisu D Teklemariam[SUP] 1 [/SUP], Anwar M Hashem[SUP] 2 3 [/SUP], Saber H Saber[SUP] 4 [/SUP], Mohammed S Almuhayawi[SUP] 2 [/SUP], Shafiul Haque[SUP] 5 [/SUP], Turki S Abujamel[SUP] 3 6 [/SUP], Steve Harakeh[SUP] 7 8 [/SUP]
Affiliations
- PMID: 36123822
- DOI: 10.1080/02648725.2022.2122297
Abstract
Bacterial co-infections are typically associated with viral respiratory tract infections and pose a significant public health problem around the world. COVID-19 infection damages tissues lining the respiratory track and regulates immune cells/cytokines leading to microbiome dysbiosis and facilitating the area to be colonized by pathogenic bacterial agents. There have been reports of different types of bacterial co-infection in COVID-19 patients. Some of these reports showed despite geographical differences and differences in hospital settings, bacterial co-infections are a major cause of morbidity and mortality in COVID-19 patients. The inappropriate use of antibiotics for bacterial infections, particularly broad-spectrum antibiotics, can also further complicate the infection process, often leading to multi drug resistance, clinical deterioration, poor prognosis, and eventually death. To this end, researchers must establish a new therapeutic approach to control SARS-CoV-2 and the associated microbial coinfections. Hence, the aim of this review is to highlight the bacterial co-infection that has been recorded in COVID-19 patients and the status of antimicrobial resistance associated with the dual infections.
Keywords: Bacteria; COVID-19; SARS-CoV-2; co-infection; patients.